Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ)
CNY13.67
+0.22 (+1.64%)
CN SHZ Healthcare Biotechnology
Address
No.1, Gold Star(Jinxing) Road
Guilin, CN
Guilin, CN
CEO
Xun Zou
Website
sanjin.com.cn
IPO
2009-07-10
ISIN CNE100000DY9
Description
Guilin Sanjin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the research, production, and distribution of traditional Chinese and natural medicines across China. Established in 1967 and headquartered in Guilin, the company's product portfolio prominently features well-known traditional Chinese medicine (TCM) brands such as Guilin watermelon frost and lozenge, Sanjin tablets, and Naomaitai capsules. Beyond these core offerings, it also manufactures a range of other TCM preparations. The company operates as a subsidiary of the broader Guilin SanJin Group Co.,Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY13.67
+0.22 (+1.64%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.20
Float Shares
131.59M
Free Float %
22.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.43% | -1.03% | +1.62% | -0.48% | -6.58% | +2.62% | +3.88% | -23.03% | +5.24% | -18.39% | -47.76% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
13.67
DCF (Unlevered)
19.49
+42.6%
DCF (Levered)
25.19
+84.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-09 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.23
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-6.8% Q1'26: +12.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-16.9% Q1'26: +16.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+28.3% ★ Q1'26: -1.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+27.8% ★ Q1'26: +29.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+23.7% ★ Q1'26: +24.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: +1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.71× ★ Q1'26: 0.72× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.39B
est: 2.04B (-31.7%)
|
1.53B
est: 2.04B (-25.1%)
|
1.62B
est: 1.65B (-2.1%)
|
1.58B
est: 1.65B (-4.0%)
|
1.64B
est: 1.81B (-9.1%)
|
1.57B
est: 2.05B (-23.7%)
|
1.96B
est: 1.97B (-0.5%)
|
2.17B
est: 2.28B (-4.8%)
|
2.19B
est: 2.24B (-2.2%)
|
2.05B
est: 2.44B (-16.2%)
|
2.68B
2.58B – 2.79B
+10.0% YoY
|
| EBITDA |
462.50M
est: 498.51M (-7.2%)
|
514.63M
est: 498.51M (+3.2%)
|
592.05M
est: 404.00M (+46.5%)
|
552.75M
est: 404.00M (+36.8%)
|
556.17M
est: 441.95M (+25.8%)
|
393.58M
est: 502.67M (-21.7%)
|
412.21M
est: 482.10M (-14.5%)
|
575.53M
est: 558.74M (+3.0%)
|
571.42M
est: 928.15M (-38.4%)
|
654.91M
est: 1.01B (-35.1%)
|
1.11B
1.07B – 1.15B
+10.0% YoY
|
| EBIT |
401.80M
est: 398.86M (+0.7%)
|
449.61M
est: 398.86M (+12.7%)
|
523.40M
est: 323.24M (+61.9%)
|
477.03M
est: 323.24M (+47.6%)
|
465.48M
est: 353.61M (+31.6%)
|
313.31M
est: 402.19M (-22.1%)
|
315.65M
est: 385.74M (-18.2%)
|
460.41M
est: 447.06M (+3.0%)
|
480.47M
est: 853.92M (-43.7%)
|
568.15M
est: 928.51M (-38.8%)
|
1.02B
982.02M – 1.06B
+10.0% YoY
|
| Net Income |
376.53M
est: 597.71M (-37.0%)
|
393.66M
est: 597.71M (-34.1%)
|
464.40M
est: 732.49M (-36.6%)
|
413.35M
est: 433.63M (-4.7%)
|
392.14M
est: 486.37M (-19.4%)
|
277.02M
est: 580.13M (-52.2%)
|
329.53M
est: 322.30M (+2.2%)
|
421.30M
est: 480.51M (-12.3%)
|
521.53M
est: 450.69M (+15.7%)
|
433.13M
est: 509.23M (-14.9%)
|
573.61M
555.69M – 591.53M
+12.6% YoY
|
| SGA |
576.30M
est: 836.72M (-31.1%)
|
630.98M
est: 836.72M (-24.6%)
|
605.88M
est: 678.09M (-10.6%)
|
573.87M
est: 678.09M (-15.4%)
|
621.99M
est: 741.79M (-16.1%)
|
622.02M
est: 843.71M (-26.3%)
|
812.68M
est: 809.19M (+0.4%)
|
920.66M
est: 937.82M (-1.8%)
|
888.26M
est: 923.40M (-3.8%)
|
817.78M
est: 1.00B (-18.6%)
|
1.10B
1.06B – 1.15B
+10.0% YoY
|
| EPS |
0.64
est: 1.02 (-37.3%)
|
0.67
est: 1.02 (-34.3%)
|
0.79
est: 1.25 (-36.8%)
|
0.70
est: 0.74 (-5.4%)
|
0.67
est: 0.83 (-19.3%)
|
0.48
est: 0.99 (-51.5%)
|
0.56
est: 0.55 (+1.8%)
|
0.72
est: 0.82 (-12.2%)
|
0.89
est: 0.77 (+15.6%)
|
0.74
est: 0.87 (-14.9%)
|
0.98
0.95 – 1.01
+12.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
465.29M
OE per share TTM
0.79
Owner's Yield
5.43%
Maintenance CapEx ratio
18.72%
Maint CapEx / Avg PPE
63.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 84.6K | 0.65% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 221.4K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 134.2K | 0.39% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 6.1K | 0.44% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 79.2K | 0.29% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 94.4K | 0.28% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 6.6K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 15.0K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 739.6K | 0.06% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 246.5K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
217.3K
Shares Outstanding
587.57M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun Li | Vice President & Secretary of the Board | — | male |
| Jie Zeng | Accounting Supervisor | — | — |
| Jingdu Lei | Director & Vice President | — | male |
| Jinqian Xu | Director, Personnel Administration Director & Manager of Human Resources Mgmt. Dept. | — | male |
| Xun Zou | Chairman of the Board & President | — | male |
| Yuangang Xie | Vice President, Chief Financial Officer & Director | — | male |
| Zhun Zou | Vice President & Non-Independent Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002275.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
